April licensing trends show Chinese biotechs expanding beyond oncology
Minhua Chu · 05/26/2022
From March 2021 to April 2022, there have been seven deals in ophthalmology. Ophthalmic drugs have become an important target of in-licensing deals in China.
READ MORE

Latest Articles

Legend Biotech's BCMA-targeted CAR-T cell therapy wins approval in Europe; HemaCell, Gracell, Adagene
Elise Mak · 22 hours ago
Legend Biotech's Carvykti has been granted conditional marketing authorization by the European Commission for the treatment of adults with relapsed and refractory multiple myeloma. More news from HemaCell, GSK, Gracell, Adagene.
News
Junshi shares more data of COVID-19 pill versus Paxlovid; Wuxi Biologics, CASI Pharma, Hengrui
Elise Mak · 2 days ago
Junshi Biosciences has shared more Phase III data of VV116, its COVID-19 oral drug, versus Pfizer's Paxlovid and said the study reached its primary endpoint and secondary efficacy endpoint. More news from Wuxi Biologics, CASI Pharma, Hengrui.
News
April licensing trends show Chinese biotechs expanding beyond oncology
Minhua Chu · 2 days ago
From March 2021 to April 2022, there have been seven deals in ophthalmology. Ophthalmic drugs have become an important target of in-licensing deals in China.
China Deals Tracker
GenEditBio closes angel and series pre-A rounds to develop gene-editing tools; Henlius
Elise Mak · 3 days ago
Beijing-based GenEditBio has raised dozens of millions of U.S. dollars in angel and Series pre-A funding to develop next-generation gene-editing tools and advance its pipeline. More news from Henlius.
News
Junshi's COVID-19 tablet meets primary endpoint in phase III trial versus Paxlovid; Sinogen, Scindy, WayShine
Elise Mak · 3 days ago
Shanghai Junshi Biosciences' VV116 tablet, an oral nucleoside analog anti-SARS-CoV-2 drug, reached its primary endpoint in a phase III registrational clinical study versus Pfizer's Paxlovid for early treatment of mild to moderate COVID-19. More news from Sinogen, Scindy, WayShine, StarMab
News
China expands use of Novartis drug Promacta to treat children as young as six
Elise Mak · 4 days ago
The NMPA has approved an expanded use for Novartis' Promacta to treat children aged between 6 and 11 with chronic ITP who have had an insufficient response to glucocorticoids and immunoglobulins.
News
China grants market exclusivity to pediatric and orphan drugs via new drug rules
Elise Mak · 5 days ago
China’s drug regulators are accelerating the development pathway of pediatric and orphan drugs through revised regulations. Biotech companies that focus on developing these drugs will be rewarded with market exclusivity.
Regulatory
Roche China Accelerator to aid nine local biotech startups; VerImmune, U-Synbio, Hansoh
Elise Mak · 7 days ago
A year after its launch in Shanghai, Roche China Accelerator said it has identified nine local innovative drugmakers to join efforts with the pharma giant. More news from VerImmune, U-Synbio, Hansoh, ACEA Pharma, CANSino, Bayer.
News
Hengrui launches Luzsana to bring drugs to North America, Europe and Japan; Meton Pharma, CTTQ, Junshi
Elise Mak · 8 days ago
Chinese pharma giant Hengrui Pharma has launched a new company named Luzsana Biotechnology to co-develop medicines and commercialize them in North America, Europe and Japan. More news from Meton Pharma, CTTQ, Junshi.
News
Pediatric drug development a new investment area in China
Shi Yingzi · 9 days ago
A drugmaker specializing in medicines for children raising nearly $15.7 million in April 2022 shows a shifting interest toward this area. Early-stage biotech companies also made up 18 of the 27 financing deals.
China Biotech Fundraising Tracker
Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement